Recent advancements at ASCO 2024 in PD-L1 and PD-1 bispecific antibodies
Review
doi: 10.1007/s12032-024-02559-3.
Affiliations
Item in Clipboard
Review
Med Oncol.
.
Abstract
Recent advancements in cancer immunotherapy have spotlighted the PD-1/PD-L1 pathway, crucial for its role in immune checkpoint regulation. Traditional inhibitors, though successful, face challenges like resistance and adverse effects. Bispecific antibodies targeting PD-1 and PD-L1 present a ground-breaking solution by simultaneously engaging multiple immune regulatory molecules. Developments in PD-1/PD-L1 bispecific antibodies up to now have been summarized, and the latest findings from the 2024 ASCO conference are presented, revealing that bispecific antibodies exhibit robust efficacy in treating various types of cancers, marking a significant step forward in cancer treatment.
Keywords:
Bispecific antibodies; Cancer immunotherapy; Immune checkpoint regulation; PD-1 inhibitors; PD-1/PD-L1 pathway; PD-L1 inhibitors.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
References
-
-
Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. https://doi.org/10.1186/s12943-019-0974-6 .
–
DOI
–
PubMed
–
PMC
-
-
-
Liu R, et al. IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: a phase I dose-escalation study. J Clin Oncol. 2024;42(16_suppl):e14506–e14506. https://doi.org/10.1200/JCO.2024.42.16_suppl.e14506 .
–
DOI
-
-
-
Wu L, et al. Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts. J Clin Oncol. 2024;42(16_suppl):5524–5524. https://doi.org/10.1200/JCO.2024.42.16_suppl.5524 .
–
DOI
-
-
-
Wu C, et al. A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC. J Clin Oncol. 2024;42(16_suppl):8533–8533. https://doi.org/10.1200/JCO.2024.42.16_suppl.8533 .
–
DOI
-
-
-
Falchook GS, et al. Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4–1BB, in advanced solid tumors. J Clin Oncol. 2024;42(16_suppl):2529–2529. https://doi.org/10.1200/JCO.2024.42.16_suppl.2529 .
–
DOI
-
MeSH terms
Substances
Fonte original PubMed